VALNEVA news, videos and press releases - Page 4
For more news please use our advanced search feature.
VALNEVA - More news...
VALNEVA - More news...
- Valneva Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Global Offering to Approximately $102.0 Million
- Valneva announces temporary trading suspension of its ordinary shares on Euronext Paris
- Valneva Announces the Pricing of its Global Offering of American Depositary Shares and Ordinary Shares
- Valneva Publishes Amendment to 2020 Universal Registration Document
- Valneva Announces Launch of Proposed Global Offering of American Depository Shares and Ordinary Shares
- Valneva Continues Expansion of Clinical Trials of its Inactivated COVID-19 Vaccine Candidate VLA2001
- Valneva Receives Notice of Termination of COVID-19 Vaccine Supply Agreement by UK Government
- Déclaration d'actions et de droits de vote de la société Valneva SE - Août 2021
- Valneva Initiates Further Phase 3 Clinical Trial for its COVID-19 Vaccine Candidate
- Valneva Reports H1 2021 Financial Results and Provides Business Update
- Valneva Awarded FDA Breakthrough Designation for its Single-Shot Chikungunya Vaccine Candidate
- Valneva Strengthens Management Team; Appoints Vincent Dequenne as SVP Operations and Joshua Drumm as VP Investor Relations
- Valneva to Host Symposium on COVID-19 and Chikungunya Vaccine Candidates at 31st European Congress of Clinical Microbiology & Infectious Diseases
- Valneva Continues Ongoing Discussions with the European Commission for Inactivated COVID-19 Vaccine Candidate
- Valneva Announces Termination of Liquidity Contract with Oddo BHF and Natixis and Publishes End of Contract Statement
- Valneva Completes Recruitment for Phase 3 Lot-to-Lot Consistency Trial of its Chikungunya Vaccine Candidate
- Déclaration d’actions et de droits de vote de la société Valneva SE – Mai 2021
- Valneva Completes Phase 3 Trial Recruitment for its Inactivated COVID-19 Vaccine Candidate
- Valneva to Participate in the World’s First COVID-19 Vaccine Booster Trial in the UK
- Citi Appointed as Depositary Bank for Valneva SE’s ADR Programme
- Valneva Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Global Offering to $107.6 Million
- VALNEVA : Déclaration d’actions et de droits de vote – Avril 2021
- Valneva announces trading resumption of its ordinary shares on Euronext Paris
- Valneva announces temporary trading suspension of its ordinary shares on Euronext Paris
- Valneva Announces the Pricing of its Initial Public Offering on Nasdaq
- Valneva Announces an Indicative Price Range of its Previously Announced Proposed Global Offering
- Valneva Announces Launch of Proposed Global Offering, Start of the Roadshow and Nasdaq Listing
- Valneva Announces Launch of Proposed Global Offering, Start of the Roadshow and Nasdaq Listing
- Valneva Initiates Pivotal Phase 3 Clinical Trial for its Inactivated, COVID-19 Vaccine Candidate using Dynavax's CpG 1018™ Adjuvant
- Valneva Initiates Phase 3 Clinical Trial for its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001
